亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Pharmacokinetic and Pharmacodynamic Effects of Multiple-dose Administration of Omarigliptin, a Once-weekly Dipeptidyl Peptidase-4 Inhibitor, in Obese Participants With and Without Type 2 Diabetes Mellitus

医学 二肽基肽酶-4抑制剂 安慰剂 药效学 药代动力学 2型糖尿病 内科学 体质指数 人口 2型糖尿病 糖尿病 二肽基肽酶-4 内分泌学 胃肠病学 药理学 替代医学 环境卫生 病理
作者
Carol Addy,Daniel Tatosian,Xiaoli S. Glasgow,Isaias Noel Gendrano,Eunkyung Kauh,Ashley Martucci,Amy O. Johnson‐Levonas,Diana Selverian,Catherine Matthews,Marie Gutierrez,John A. Wagner,S. Aubrey Stoch
出处
期刊:Clinical Therapeutics [Elsevier BV]
卷期号:38 (3): 516-530 被引量:25
标识
DOI:10.1016/j.clinthera.2015.12.020
摘要

Omarigliptin (MK-3102) is a potent, oral, long-acting dipeptidyl peptidase (DPP)-4 inhibitor approved in Japan and in global development as a once-weekly treatment for type 2 diabetes mellitus (T2DM). The aim of this study was to investigate the pharmacokinetic (PK) and pharmacodynamic (PD) effects of omarigliptin in obese participants with and without T2DM.This was a Phase I, randomized, double-blind, placebo-controlled, multiple-dose study of 50-mg omarigliptin administered once weekly for 4 weeks. Participants included 24 obese but otherwise healthy subjects (panel A; omarigliptin, n = 18; placebo, n = 6) and 8 obese patients with T2DM (treatment naive, hemoglobin A1c ≥ 6.5% and ≤ 10.0% [panel B]; omarigliptin, n = 6; placebo, n = 2). Participants were 45 to 65 years of age with a body mass index of ≥ 30 and ≤ 40 kg/m(2). Blood sampling occurred at select time points, depending on the study panel, to evaluate the PK properties of omarigliptin, DPP-4 activity, active glucagon-like peptide 1 levels, and plasma glucose concentrations. Body weight was an exploratory end point. Due to sparse sampling in panel A, a thorough PK analysis was performed in obese patients with T2DM (panel B) only. PD analyses were performed in the overall study population (pooled panels A and B).PK profiles in obese participants with and without T2DM were similar to those observed in nonobese reference subjects (historical data). Steady state was achieved after 1 or 2 weekly doses in obese participants with and without T2DM. In obese patients with T2DM, omarigliptin was rapidly absorbed, with a median Tmax of 1 to 2.5 hours (days 1 and 22). Compared with those in reference subjects, the geometric mean ratios (95% CI) (Obese T2DM/reference) for steady-state plasma AUC0-168h, Cmax, and C168h were 0.80 (0.65-0.98), 0.86 (0.53-1.41), and 1.08 (0.88-1.33), respectively. Trough DPP-4 activity was inhibited by ~90%; postprandial (PP) 4-hour weighted mean active GLP-1 concentrations were increased ~2-fold; and PP glucose was significantly reduced with omarigliptin versus placebo in the pooled population. Omarigliptin was generally well-tolerated in the pooled population, and there were no hypoglycemic events. Consistent with other DPP-4 inhibitors, omarigliptin had no effect on body weight in this short-duration study.The administration of omarigliptin was generally well-tolerated in obese participants with and without T2DM, and the favorable PK and PD profiles support once-weekly dosing. Omarigliptin may provide an important once-weekly treatment option for patients with T2DM. ClinicalTrials.gov identifier: NCT01088711.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pegasus0802完成签到 ,获得积分10
2秒前
5823364完成签到,获得积分10
20秒前
automan完成签到,获得积分10
22秒前
天亮polar完成签到,获得积分10
23秒前
59秒前
1分钟前
1分钟前
朴实云应发布了新的文献求助10
1分钟前
林子青完成签到,获得积分10
1分钟前
核桃发布了新的文献求助30
2分钟前
李健应助reerwt采纳,获得10
2分钟前
2分钟前
ICSSCI发布了新的文献求助10
2分钟前
2分钟前
刘宇童给刘宇童的求助进行了留言
2分钟前
reerwt发布了新的文献求助10
2分钟前
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
ICSSCI完成签到,获得积分10
2分钟前
3分钟前
董可以发布了新的文献求助10
3分钟前
风华正茂完成签到,获得积分10
3分钟前
3分钟前
4分钟前
jimmy_bytheway完成签到,获得积分0
4分钟前
桃桃发布了新的文献求助10
4分钟前
可爱的函函应助桃桃采纳,获得10
4分钟前
4分钟前
4分钟前
4分钟前
4分钟前
NexusExplorer应助科研通管家采纳,获得10
4分钟前
所所应助爱笑的毛衣采纳,获得10
4分钟前
5分钟前
5分钟前
duan完成签到 ,获得积分10
5分钟前
holder完成签到,获得积分10
5分钟前
5分钟前
沐白发布了新的文献求助10
5分钟前
高分求助中
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3990049
求助须知:如何正确求助?哪些是违规求助? 3532108
关于积分的说明 11256369
捐赠科研通 3270998
什么是DOI,文献DOI怎么找? 1805166
邀请新用户注册赠送积分活动 882270
科研通“疑难数据库(出版商)”最低求助积分说明 809228